Pharmakoangiographie mit Angiotensin

Novak, D; Weber, J.

doi:10.1055/s-0029-1230336

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51-55 This phenomenon was recognized in 1970's during diagnostic angiography for tumor localization and was termed “pharmaco-angiography”. 56 During diagnostic angiography, vaso-constricting agents including alpha receptor agonists were injected to constrict normal vessels while accentuating tumor vessels. 57, 58 Later, pharmaco-angiography was used to constrict vessels after the delivery of nano-drug therapy to prolong the exposure of the tumor to the therapy.…”

Section: Improving the Enhanced Permeability And Retention (Epr) Ementioning

confidence: 99%

Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?

2014

View full text Add to dashboard Cite

Nano-sized therapeutic agents have several advantages over low molecular weight agents such as a larger loading capacity, the ability to protect the payload until delivery, more specific targeting due to multivalency and the opportunity for controlled/sustained release. However, the delivery of nano-sized agents into cancer tissue is problematic because it mostly relies on the enhanced permeability and retention (EPR) effect that depends on the leaky nature of the tumor vasculature and the prolonged circulation of nano-sized agents, allowing slow but uneven accumulation in the tumor bed. Delivery of nano-sized agents is dependent on several factors that influence the EPR effect; 1. Regional blood flow to the tumor, 2. Permeability of the tumor vasculature, 3. Structural barriers imposed by perivascular tumor cells and extracellular matrix, 4. Intratumoral pressure. In this review, these factors will be described and methods to enhance nano-agent delivery will be reviewed.

show abstract

Section: Improving the Enhanced Permeability And Retention (Epr) Ementioning

confidence: 99%

Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?

2014

View full text Add to dashboard Cite

show abstract

“…33 This phenomenon was recognized in the 1970s during diagnostic angiography for tumor localization and was termed “pharmaco-angiography”. 34 During diagnostic angiography, vaso-constricting agents including alpha receptor agonists were injected via a catheter to constrict normal vessels while accentuating tumor vessels. 35 , 36 Later, pharmaco-angiography was used to constrict vessels after the delivery of nanodrug therapy to reduce washout and increase exposure of the tumor to the therapy.…”

Section: How To Improve Cancer Drug Deliverymentioning

confidence: 99%

Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates

et al. 2014

View full text Add to dashboard Cite

In order to efficiently deliver anticancer agents to tumors, biocompatible nanoparticles or bioconjugates, including antibody–drug conjugates (ADCs), have recently been designed, synthesized, and tested, some even in clinical trials. Controlled delivery can be enhanced by changing specific design characteristics of the bioconjugate such as its size, the nature of the payload, and the surface features. The delivery of macromolecular drugs to cancers largely relies on the leaky nature of the tumor vasculature compared with healthy vessels in normal organs. When administered intravenously, macromolecular bioconjugates and nanosized agents tend to circulate for prolonged times, unless they are small enough to be excreted by the kidney or stealthy enough to evade the macrophage phagocytic system (MPS), formerly the reticulo-endothelial system (RES). Therefore, macromolecular bioconjugates and nanosized agents with long circulation times leak preferentially into tumor tissue through permeable tumor vessels and are then retained in the tumor bed due to reduced lymphatic drainage. This process is known as the enhanced permeability and retention (EPR) effect. However, success of cancer drug delivery only relying on the EPR effect is still limited. To cure cancer patients, further improvement of drug delivery is required by both designing superior agents and enhancing EPR effects. In this Review, we describe the basis of macromolecular or nanosized bioconjugate delivery into cancer tissue and discuss current diagnostic methods for evaluating leakiness of the tumor vasculature. Then, we discuss methods to augment conventional “permeability and retention” effects for macromolecular or nanosized bioconjugates in cancer tissue.

show abstract